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The CD8C T-cell response comprises terminally differentiated effector cells and antigen-experienced memory T cells.
The latter encompass central (TCM) and effector (TEM) memory cells. TCM cells are superior in their protection against
viral and bacterial challenges and mediation of antitumor immunity due to their higher proliferative ability upon
antigen re-encounter. Deﬁning a mechanism to enhance TCM cells and delay terminal differentiation of CD8
C T cells is
crucial for cancer immune therapy, as it can promote a better tumor immune response. The differentiation of CD8C
memory T cells is thought to be coordinated by the phosphoinositide 3-kinase (PI3K)/Akt pathway. We, therefore,
investigated the role of Akt isoforms in the differentiation and proliferation of memory CD8C T cells. We found that
Akt1 and Akt2, but not Akt3, drive the terminal differentiation of CD8C T cells, and their inhibition enhances the
therapeutically superior TCM phenotype. Furthermore, the inhibition of Akt1 and Akt2, but not Akt 3, delays CD8
C T-cell
exhaustion and preserves na€ıve and TCM CD8
C T cells, thus enhancing their proliferative ability and survival and
prolonging their cytokine and Granzyme B production ability. Here, we deﬁne a mechanism in which proliferative
potential, function, and survival of CD8C T cells are enhanced by maintaining a reservoir of TCM and na€ıve cells using
only Akt1 and Akt2 inhibition. Therefore, our ﬁndings strongly suggest the utility of using Akt1 and Akt2 inhibitors to
modulate CD8C T cells, both for adoptive cell transfer and vaccine-based cancer immune therapies.
Introduction
Upon antigen encounter and during the T-cell response,
CD8C T cells comprise effector and memory T cells.1,2 Although
effector CD8C T cells become terminally differentiated and are
eliminated by apoptosis following antigen clearance, approxi-
mately 10% of the remaining antigen-specific CD8C T cells
become memory T cells.2 There are 2 types of CD8C memory T
cells: central (TCM) and effector (TEM) memory T cells.
2,3 Unlike
TEM cells, TCM cells express a high level of CD62L and CCR7
and secrete high levels of interleukin (IL)-2 that correlates with
their proliferative ability.2-4 It is, therefore, no surprise that TCM
cells are superior in their ability to protect against viral and bacte-
rial challenges when compared to TEM cells.
4,5
The quality of tumor antigen-specific CD8C T cells is crucial
for an effective tumor immune response.6 Adoptive cell transfer
(ACT) of tumor-reactive CD8C TCM cells has been shown to be
a superior mediator of therapeutic antitumor immunity com-
pared to TEM cells, because of their greater proliferative capacity
upon antigen re-encounter.4,5,7,8 Accordingly, understanding the
regulation of CD8C T cells into TEM or TCM cells is crucial, as
defining a mechanism to enhance TCM cells and delay terminal
differentiation of CD8C T cells can promote a better tumor
immune response.
The duration and intensity of antigenic stimulation con-
trol the magnitude of the CD8C T-cell response as well as
their differentiation into effector and memory CD8C T cells.
This differentiation is coordinated by the phosphoinositide 3-
kinase (PI3K)/Akt pathway.1 It has been established that Akt
activation regulates the differentiation of CD8C T cells into
effector and memory T cells, where sustained Akt activation
leads to terminal differentiation of effector CD8C T cells,
whereas inhibition of Akt in vivo increases the number of
memory CD8C T cells.9
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ORIGINAL RESEARCH
Here, we report that Akt1 and Akt2, but not Akt3, drive the
terminal differentiation of CD8C T cells, and their inhibition
enhances the therapeutically superior central memory phenotype.
Furthermore, the inhibition of Akt1 and Akt2, but not Akt 3,
delays CD8C T-cell exhaustion and preserves a reservoir of na€ıve
and TCM CD8
C T cells, thus enhancing their proliferative ability
and survival and prolonging their cytokine production ability.
Agents that slow down the terminal differentiation of CD8C
T cells without substantially impacting their proliferation are
needed. Here, we define a mechanism in which proliferative
potential, function, and survival are enhanced by maintaining a
reservoir of TCM and na€ıve cells by inhibiting only Akt1 and
Akt2. Therefore, our findings strongly suggest the utility of using
Akt1 and Akt2 inhibitors to modulate CD8C T cells as part of
different cancer immune therapy regimens.
Results
Akt inhibition enhances the central memory phenotype
of CD8C T cells by diminishing their terminal differentiation
and increasing their proliferative ability and survival
The TCM CD8
C T cells are superior mediators of therapeutic
antitumor immunity due to their greater proliferative capacity
upon antigen re-encounter.4,5,7,8 Many T-cell functions are gov-
erned by PI3K/Akt signaling, including proliferation, survival,
migration, and metabolism.10,11 To test the role of Akt in the dif-
ferentiation and proliferation of CD8C T cells, we tested the effect
of the pan Akt inhibitors MK-2206 and AZD5363 on stimulated
CD8C T cells. This was done using unfractionated splenocytes
from pMel-1 mice activated with 1 mmol/L gp10025–33.
The phenotype of CD8C T cells was assessed after 3 d of stim-
ulation. We found that MK–2206-treated cells consisted mainly
of TCM cells (CD62L
hiCD44hi) and displayed a higher percent-
age of na€ıve cells (CD62LhiCD44lo) (Fig. 1A). On the other
hand, the majority of non–MK-2206-treated cells were TEM cells
(CD62LloCD44hi). This was observed at all the concentrations
used(Fig. 1A), and plateaued at the 0.67 mmol/L concentration,
which was, therefore, used as the optimal dose. The same pattern
was also detected in AZD5363-treated cells (Fig. S1A), although
the effect on CD8C T cells was not as prominent as that with
MK-2206 at the concentration used. This shows that Akt inhibi-
tion retards the terminal differentiation of CD8C T cells and
holds them in the central memory and earlier differentiation
stages. The same effect was seen after the second and third stimu-
lation with gp10025–33 on days 7, 14, and 21 in the presence of
the Akt inhibitors (Fig. S2 and data not shown). It is worth men-
tioning that, although the percentage of TCM in inhibitor-treated
cells decreased following the third and fourth stimulations, it was
significantly higher than the percentage in the non-treated cells.
This decrease could be attributed to the effect of consecutive
stimulations with the antigen, which results in memory recall of
TCM that eventually differentiate into TEM and effector cells.
Taken together, these data show that Akt inhibition preserves a
healthy reservoir of TCM cells even after several encounters with
the antigen.
Because TCM CD8
C T cells are known to possess a greater
proliferative ability than TEM cells upon antigen re-encoun-
ter,4,5,7,8 we then assessed the proliferation of CD8C T cells. Fol-
lowing the first 3 d of stimulation (to differentiate antigen-
specific CD8C T cells), we found that the proliferation of CD8C
T cells treated with MK-2206 or AZD5363 was inhibited in a
dose-dependent manner as measured by Violet cell trace (VCT)
dilution, as expected (Fig. 1B and Fig. S1B). However, surpris-
ingly, with further stimulation (on days 7, 14, and 21), the MK–
2206-treated CD8C T cells were found to expand at a signifi-
cantly higher rate than the non-treated cells (Fig. 1B). On the
other hand, the non-treated cells lost the ability to expand follow-
ing the third stimulation. This clearly shows that Akt inhibition
leads to enhanced longevity and prolonged cell survival of the
CD8C T cells. The same effect was observed with AZD5363,
although to a lesser extent than with MK-2206 at the concentra-
tion used (Fig. S1B).
Interestingly, we found that CD8C T cells treated with MK-
2206 maintained high expression levels of CD62L and CD127
(markers associated with high proliferative potential). This corre-
lates with the enhanced proliferation ability of the TCM cells
treated with the inhibitor. These high levels were observed on
days 3, 7, 14, and 21 (Fig. 1C and D).
The ability of CD8C T cells to proliferate was further assessed
by measuring the level of IL-2 secretion, which is diminished in
terminally differentiated CD8C T cells. We found that CD8C T
cells treated with MK-2206 maintained a significantly high level
of IL-2 secretion when re-stimulated on days 7 and 14 (Fig. 1B).
The increase in longevity and survival observed in the MK–
2206-treated CD8C T cells prompted us to assess the expression
level of KLRG-1, which is upregulated in terminally differenti-
ated cells. We found that Akt inhibition maintained a low level
of KLRG-1 after the second and third stimulations, whereas the
non-treated CD8C T cells expressed a significantly higher level of
this marker (Fig. 1E). The ability of MK-2206 to delay the
exhaustion of CD8C T cells corresponds to the cells’ ability to
survive and expand in response to more stimulations than the
non-treated cells (Fig. 1B). The same effect was observed when
cells were treated with the Akt inhibitor AZD5363 (Fig. S1C-
E), although to a lesser extent than with MK-2206 at the concen-
tration used.
Taken together, these data show that Akt inhibition preserves
TCM cells, thus enhancing their proliferative potential and sur-
vival while delaying the terminal differentiation and exhaustion
of CD8C T cells.
Akt inhibition rescues the ability of CD8C T cells to produce
cytotoxic cytokines and granzyme B after multiple stimulations
We have shown that targeting Akt using pan Akt inhibitors
enhances proliferation, preserves the TCM phenotype, delays
exhaustion, and conserves a larger pool of na€ıve cells. To assess
the function of TCM cells, the secretion levels of interferon
gamma (IFNg) and tumor necrosis factor (TNF) were tested.
The CD8C T cells were re-stimulated on days 7 and 14 with
gp10025–33 and the level of IFNg and TNF production after
24 h was assessed. After the second stimulation, MK–2206-
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treated and non-treated cells produced high and comparable lev-
els of IFNg and TNF in response to antigen re-encounter
(Fig. 2A). After the third stimulation, the secretion of IFNg and
TNF dropped significantly; however, Akt inhibition rescued the
ability of CD8C T cells to produce these cytokines, as their
ability to secrete IFNg and TNF was maintained at a significantly
higher level (Fig. 2A and B). This suggests that CD8C T cells
undergo terminal differentiation and reach exhaustion, thus los-
ing their ability to secrete IFNg and TNF upon several encoun-
ters with the antigen. Akt inhibition can clearly rescue the ability
Figure 1. For ﬁgure legend, see next page.
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of CD8C T cells to produce cytotoxic cytokines even with further
stimulation.
To further test the cytotoxic ability of the CD8C T cells, we
assessed the level of Granzyme B production by intracellular stain-
ing. Following the first stimulation, all of the cells produced Gran-
zyme B (in comparison to na€ıve cells); however, MK–2206-treated
cells produced a lower level in comparison to the non-treated cells.
Remarkably, following the second stimulation, a higher percentage
of MK–2206-treated cells produced higher levels of Granzyme B
(Fig. 2C). Interestingly, a small population of MK–2206-treated
cells produced a higher level of Granzyme B than the rest of the
cells, and these corresponded to the TCM population with the
highest CD62L expression level (data not shown).
The maintained levels of IFNg and TNF secretion suggest that
CD8C T cells do not lose their cytotoxic functionality as a result
of Akt inhibition. In fact, Akt inhibition enhances their prolifer-
ative ability and survival by delaying their terminal differentiation
and prolongs their ability to produce cytotoxic cytokines.
Akt 1 and Akt 2 are the two isoforms responsible
for terminal differentiation of CD8 T cells
We have shown that Akt inhibition in CD8C T cells delays
their terminal differentiation, preserves TCM cells, enhances their
proliferative ability and cytokine secretion, and prolongs their
survival. The role of specific Akt isoforms (Akt1, -2, and -3) in
the development, proliferation and function of CD8C T cells is
only known during thymic development, where Akt1 and Akt2
are the main isoforms contributing to the transition toward the
double-positive (CD4CCD8C) stage and are involved in the dif-
ferentiation of single-positive T cells.12,13 To further dissect the
role of specific Akt isoforms in the differentiation and prolifera-
tion of CD8C T cells, we tested the effect of Akt1 and Akt2 inhi-
bition using an Akt-1/2 inhibitor on stimulated CD8C T cells.
This was done using unfractionated splenocytes from pMel-1
mice activated with 1 mmol/L gp10025–33.
The phenotype of the cells was assessed after 3 d of stimulation.
Similar to what we observed with the pan Akt inhibitors, CD8C T
cells treatedwith theAkt-1/2 inhibitor consistedmainlyof TCMcells
and displayed a higher percentage of na€ıve cells (Fig. 3A). On the
other hand, themajority of the non-treated CD8CT cells were TEM
cells. This effectwas persistent even after the second and third stimu-
lations (Fig. 2). These findings suggest that Akt1 and -2 are the
isoforms responsible for terminal differentiation of CD8C T cells
and that their inhibitionmaintainsCD8Tcells inearlier stagesofdif-
ferentiation (na€ıveandTCM).
To test if the TCM phenotype generated by the inhibition of
Akt1 and -2 possesses an enhanced proliferative ability, the pro-
liferation of CD8C T cells was assessed after 3 d of stimulation.
We found that the proliferation of CD8 T cells treated with Akt-
1/2 inhibitor was inhibited in a dose-dependent manner
(Fig. 3B). Additionally, the inhibition of Akt1 and Akt2 signifi-
cantly enhanced the proliferative ability of CD8C T cells with
further stimulations (days 7 and 14) (Fig. 3B). Treatment of
CD8C T cells with an Akt-1/2 inhibitor also maintained high
expression levels of CD62L and CD127 (Fig. 3C and D) and
high secretion levels of IL-2 (data not shown), consistent with
the enhanced proliferative ability of TCM cells.
Similar to what we observed with pan Akt inhibitors, treat-
ment of CD8 T cells with an Akt-1/2 inhibitor prolonged their
survival and delayed their exhaustion, as evidenced by the main-
tained proliferative ability and the low levels of KLRG-1 follow-
ing multiple stimulations (Fig. 3E).
Treating the cells with an Akt-1/2 inhibitor also preserved
high levels of TNF and IFNg secretion (data not shown), sug-
gesting an enhanced cytotoxic functionality of CD8C T cells.
Remarkably, the inhibition of Akt1 and Akt 2 did not signifi-
cantly affect the production of Granzyme B following the first
stimulation, as the cells produced a comparable level to the non-
treated cells (Fig. 2C). Following the second stimulation, a
higher percentage of Akt–1/2-treated cells produced higher levels
of Granzyme B (Fig. 2C). Similar to treatment with pan inhibi-
tors, a small population of Akt–1/2-treated cells produced a
higher level of Granzyme B than the rest of the cells, and these
corresponded to the TCM population with highest CD62L
expression level (data not shown).
To rule out any influence of nonspecific inhibition of different
isoforms and kinases using Akt inhibitors, the phenotype of stim-
ulated CD8C T cells from Akt1, -2, and -3 knockout (KO) and
wild-type (WT) mice was assessed. After 7 d of stimulation, the
highest percentage of TCM cells was observed from Akt1 KO
mice, followed by Akt2 KO CD8C T cells. The CD8C T cells
from both WT and Akt3 KO mice had comparable levels of
TCM cells, which were significantly lower than the Akt1 and -2
KO CD8C T cells (Fig. 4A).
Figure 1 (see previous page). Akt inhibition preserves the TCM phenotype and enhances the proliferative ability of CD8
C T cells. Non-fractionated sple-
nocytes from pMel-1 mice were stained with VCT and activated with gp10025–33 peptide (1 mmol/L) in the presence or absence of MK-2206 (0.67, 2, and
6 mmol/L). The concentration of the inhibitors was maintained throughout the experiment. The cells were re-stimulated with gp10025–33 peptide on
days 7, 14, and 21 and their phenotype and proliferation were assessed. The gated cells were viable (7AAD-) CD8CVb13C. The data are representative
of at least 4 independent experiments. (A) In this representative example, CD8C T cells from a na€ıve spleen (far left) are mainly (72%) na€ıve cells
(CD62LhiCD44lo). Sixty-seven percent (67%) of non–MK-2206-treated CD8C T cells (third graph from left) are TEM cells (CD62LloCD44hi) and less than 1%
are na€ıve cells (CD62LhiCD44lo). This changes when cells are treated with MK-2206 (far right), as 65% of the cells possess the TCM phenotype
(CD62LhiCD44hi) and 14% are na€ıve cells (CD62LhiCD44lo). (B) After 3 d of stimulation, the proliferation of CD8C T cells was inhibited in a dose-dependent
manner by MK-2206 (VCT dilution) (far left). CD8C T cells treated with MK-2206 expand at a signiﬁcantly high rate with further stimulations (middle
graph; data normalized to the non-treated control [GP100]). MK–2206-treated CD8C T cells secrete signiﬁcantly higher levels of IL-2 following stimula-
tions 2 and 3, which is consistent with their higher proliferative potential (far right). *, P < 0.05; **, P < 0.01; ****, P < 0.0001. (C) Akt inhibition by MK-
2206 maintains a high level of CD62L expression in CD8C T cells on Day 3, and on Day 7 after each stimulation with gp100. (D) Akt inhibition by MK-
2206 maintains high levels of CD127 in CD8C T cells on Day 3, and on Day 7 after each stimulation with gp100. (E) Akt inhibition by MK-2206 inhibits the
upregulation of KLRG-1 in CD8C T cells after the second and third stimulations with gp100.
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The Akt1 KO cells expressed a higher
level of CD62L and CD127 than Akt2
KO cells, which in turn expressed higher
levels of these markers than WT and
Akt3 KO cells (Fig. 4B and C). How-
ever, CD8C T cells from WT and from
different Akt KO mice did not show any
differences in proliferation after several
stimulations (data not shown). This
could be explained by compensation
from the different isoforms once the
CD8C T cells are stimulated in vitro.
To assess the contribution of each
Akt isoform to the differentiation of
TCM cells, stimulated CD8
C T cells
from WT and Akt KO mice were
treated with the pan Akt and Akt-1/2
inhibitors. Interestingly, cells from all
the Akt KO mice and from WT mice
behaved similarly, where the inhibition
of Akt resulted in the enhancement of
the TCM phenotype (Fig. 5). In Akt1
and -2 KO cells, the inhibitors target
the existing isoform, thus enhancing
the effect of the absent isoform. There-
fore, TCM cells from Akt1 and Akt2
KO mice are maintained at comparable
levels to WT treated with the same
inhibitors. On the other hand, the
absence of Akt3 in the KO mice did
not affect the differentiation of CD8C
T cells, and the inhibition of the exist-
ing isoforms (Akt1 and Akt2) resulted
in a similar outcome to Akt inhibition
in WT mice. This finding suggests
that, unlike Akt1 and -2, Akt3 does
not play a significant role in the devel-
opment of CD62LhiCD44hiCD8C T
cells.
Taken together, our data demonstrate
that the inhibition of Akt1 and -2, but
not Akt 3, mitigates the terminal differ-
entiation of CD8C T cells and preserves
TCM cells, thus enhancing their prolifer-
ative potential, longevity, and survival
and rescues their ability to produce
cytokines.
Discussion
During the T-cell response, CD8C T cells comprise effector
and memory T cells.1,2 CD8C memory T cells can be classified
into TCM and TEM cells.
2,3 The TCM cells are superior in their
ability to protect against viral and bacterial challenges 4,5 and
mediation of therapeutic antitumor immunity when compared
to TEM cells, due to their greater proliferative capacity upon anti-
gen re-encounter.4,5,7,8
Multiple T-cell functions are governed by PI3K/Akt signaling,
including proliferation, survival, migration, and metabolism.10,11
In fact, the differentiation of CD8C cells into memory T cells is
thought to be coordinated, at least in part, by the PI3K/Akt path-
way.1,14,15 Sustained Akt activation leads to terminal
Figure 2. Akt inhibition by MK-2206 maintains a high level of IFNg and TNF secretion in CD8C T cells.
CD8C T cells from pMel-1 mice were stimulated with gp10025–33 peptide (1 mmol/L) in the presence
or absence of MK-2206 (0.67 mmol/L). On days 7 and 14, CD8C T cells were re-stimulated with
gp10025–33 peptide and the IFNg and TNF levels in the supernatant were assessed after 24 h using
CBA. Granzyme B expression was assessed on days 7 and 14. The data are representative of at least 2
independent experiments. (A) The ability of CD8C T cells to produce IFNg with subsequent stimula-
tions is signiﬁcantly diminished. CD8C T cells treated with MK-2206 maintain their ability to secrete
IFNg with further stimulations. *, P < 0.05; ****, P < 0.0001. (B) CD8C T cells treated with MK-2206
produce signiﬁcantly higher levels of TNF and maintain this ability with further stimulations. *, P <
0.05. (C) Following the ﬁrst stimulations, all the cells produce Granzyme B. A higher percentage of
CD8C T cells treated with MK-2206 or Akt-1/2 inhibitor produce a high level of Granzyme B following
the second stimulation.
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differentiation of effector CD8C T cells, whereas inhibition of
Akt in vivo increases the number of memory CD8C T cells,9 and
the downstream inhibition of mTOR augments the functional
quality of cytotoxic CD8C T-cell responses by prompting a CD8
memory phenotype.14-16 However, mechanisms that enhance the
TCM phenotype and delay the terminal differentiation of CD8
C
T cells without significantly impacting their proliferation and
function are still needed.
Figure 3. For ﬁgure legend, see next page.
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Here, we show, or the first time, that the Akt1 and -2 isoforms
drive the terminal differentiation of antigen-specific CD8C T
cells. We further report that the inhibition of Akt1 and -2 delays
the exhaustion of CD8C T cells, prolongs their survival, preserves
a remarkably high percentage of TCM cells, and significantly
increases their proliferative potential upon re-encountering the
antigen.
Our data show that Akt1 and -2 inhibition enhances the pro-
liferative potential of CD8 cells and maintains a high expression
of CD62L and CD127, while mitigating their exhaustion.
Figure 3 (see previous page). The Inhibition of Akt1 and Akt2 preserves TCM cells and enhances the proliferative ability of CD8
C T cells. Non-fractionated
splenocytes from pMel-1 mice were stained with VCT and activated with gp10025–33 peptide (1 mmol/L) in the presence or absence of Akt-1/2 inhibitor
(2.2, 6.7, and 20.1 mmol/L). The cells were re-stimulated with gp10025–33 on days 7, 14, and 21. The gated cells were viable (7AAD-) CD8CVb13C. (A)
Akt1 and Akt2 inhibition preserves the TCM phenotype. In this representative example, 76% of non-treated CD8
C T cells are TEM cells (CD62LloCD44hi)
and less than 1% are na€ıve cells (CD62LhiCD44lo), whereas CD8C T cells treated with an Akt-1/2 inhibitor consist of 76% TCM cells (CD62LhiCD44hi) and
22% na€ıve cells (CD62LhiCD44lo). (B) The proliferation of CD8C T cells is inhibited by the Akt-1/2 inhibitor in a dose-dependent manner (Day 3). The
expansion of CD8C T cells treated with the inhibitor is signiﬁcantly enhanced with further stimulations. Data are normalized to the non-treated control
(GP100). *, P < 0.05. (C) Akt1 and Akt2 inhibition maintains a high level of CD62L on Day 3, and on Day 7 after each stimulation. (D) Akt1 and Akt2 inhibi-
tion maintains a high level of CD127 on Day 3, and on Day 7 after each stimulation. (E) Akt1 and Akt2 inhibition mitigates the upregulation of KLRG-1 in
CD8C T cells after the second and third stimulations. Following the third stimulation, the KLRG-1 level was dramatically increased and, therefore, the biex-
ponential scale of the graph had to be adjusted for presentation purposes.
Figure 4. The absence of Akt1 and Akt2 isoforms, but not Akt3, preserves the TCM phenotype. Enriched CD8
C T cells from Akt1, -2, and -3 KO and WT
mice were stimulated with anti-CD3 (1 mg/mL) and co-stimulated with anti-CD28 (2.5 mg/mL) antibodies. The phenotype of the cells was assessed on
Day 7. The gated cells were viable (7AAD-) CD8
C. (A) In this representative example, WT CD8C T cells consisted of 83% TEM cells (CD62LloCD44hi). Akt1
KO CD8C T cells consisted of 55% TCM cells (CD62LhiCD44hi), with 43% of the cells being TEM cells. Akt2 KO CD8 T cells consist of 36% TCM and 63%
TEM cells. Akt3 KO CD8
C T cells consisted of 86% TEM cells, whereas only 12% were TCM cells. (B) Akt1 KO cells express a higher level of CD62L than Akt2
KO cells, which in turn express higher levels of these markers than WT and Akt3 KO cells that express similar levels. (C) Akt1 KO cells express a higher
level of CD127 than Akt2 KO cells, which in turn express higher levels of these markers than WT and Akt3 KO cells that express similar levels.
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Figure 5. Akt inhibition preserves the TCM phenotype in WT and Akt KO mice. Enriched CD8
C T cells from Akt1, -2, and -3 KO and WT mice were stimu-
lated anti-CD3 (1 mg/mL) and co-stimulated with anti-CD28 (2.5 mg/mL) antibodies in the presence or absence of MK-2206 (0.67 mmol/L) or an Akt-1/2
inhibitor (2.2 mmol/L). The phenotype of the cells was assessed on Day 7. The gated cells were viable (7AAD-) CD8
C. (A) Untreated CD8C T cells from WT
mice consist mainly of TEM cells, whereas those treated with MK-2206 or Akt-1/2 inhibitors consist mainly of TCM cells. (B) CD8
C T cells from Akt1 KO mice
possess signiﬁcantly more TCM cells than WT without any inhibitors. Once treated with MK-2206 or Akt-1/2 inhibitors, more TCMcells (with a higher
CD62L expression) are maintained comparable to treated WT cells. (C) CD8C T cells from Akt2 KO mice possess signiﬁcantly more TCM cells than WT with-
out any treatments, although less than that observed from Akt1 KO mice. Treatment with MK-2206 or Akt-1/2 inhibitors maintains a signiﬁcantly higher
percentage of TCM cells comparable to WT and Akt1 KO treated cells. (D) Similar to WT, CD8
C T cells from Akt3 KO mice consist mainly of TEM cells. Treat-
ment with MK-2206 or Akt-1/2 inhibitors maintains a signiﬁcantly higher percentage of TCM cells comparable to WT and Akt1 and -2 KO treated cells.
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Interestingly, inhibition of mTOR by rapamycin has been
shown to enhance the memory phenotype of CD8C T cells as a
result of modulating the functional quality of CD8C T cells
rather than their proliferation.14-16 In fact, in the tumor microen-
vironment, mTOR inhibition leads to a decrease in the prolifera-
tion of CD8C T cells by direct inhibition coupled with a
significant increase in the suppressive regulatory T-cell (Treg)
population.17 Rapamycin has been shown to support the prolifer-
ation and survival of Treg cells 18-21 due to a feedback loop where
mTOR inhibition results in PI3K-dependent Akt activation,
which sustains signaling through mTOR.22 Accordingly, anti-
body-based depletion of Treg cells was proposed recently as a
strategy to counteract this inhibition of CD8C T cells when rapa-
mycin is used to augment memory T cells.17 Although this sug-
gested strategy can minimize the suppression of CD8C T cells by
Tregs, it does not overcome the direct proliferation inhibition
exerted on CD8C cells by rapamycin. Here, we demonstrate that
inhibition of the PI3K/Akt pathway at the level of Akt signifi-
cantly enhances the proliferation of memory CD8C T cells. Fur-
thermore, we have recently shown that PI3K/Akt pathway
inhibitors selectively target Tregs with resultant significant
enhancement of antitumor immune response, including a signifi-
cant decrease in Treg cells and increase in CD8C T cells within
the tumor microenvironment.23 Therefore, using Akt inhibitors
can simultaneously enhance the effector arm by augmenting the
memory CD8C T cells and diminish the suppressive arm by
selectively inhibiting Treg cells.
The CD8C T cells progressively lose IL-2 production as a
function of differentiation from na€ıve to effector cells.3 Here, we
show that Akt inhibition in CD8C T cells maintains a signifi-
cantly higher level of IL-2 secretion. This is consistent with their
maintained ability to proliferate and their phenotype as TCM
cells. Remarkably, the enhanced proliferative ability of CD8C T
cells exerted by Akt inhibition is isoform-specific, suggesting the
possibility of precise targeting of Akt1 and -2 to modulate the
CD8C T-cell response with minimal effects on other cellular
functions.
Additionally, we show that Akt1 and -2 inhibition can rescue
the ability of CD8C T cells to secrete high levels of TNF and
IFNg and produce Granzyme B, even following multiple stimu-
lations, thus suggesting a prolonged and potent antitumor cyto-
toxic ability. This suggests the use of Akt isoform-specific
inhibitors to produce a sustained and powerful antitumor T-cell
response when combined with different cancer immune
therapies.
Our work shows that Akt1 and Akt2 inhibition leads to the
preservation of a percentage of na€ıve CD8C T cells. It has been
shown that na€ıve CD8C T cells have greater proliferative poten-
tial 24,25 and display elevated levels of IL-2 and IFNg secretion
following secondary stimulations.24 Additionally, effector T cells
derived from na€ıve T cells were found to promote more potent
in vivo antitumor activity.24,25 Therefore, our data show that
Akt1 and Akt2 inhibition maintains a higher percentage of both
na€ıve and TCM cells, which are both superior mediators of antitu-
mor activity in comparison to effector and TEM CD8
C T
cells.4,5,7,8,24,25
To rule out any influence of undesired inhibition of different
isoforms and different kinases using Akt inhibitors, the pheno-
type of CD8C T cells from different Akt isoform KO mice was
assessed. Our data confirm that the complete absence of Akt1,
and to a lesser extent Akt2, display an increased proportion of
TCM developing upon stimulation, when compared to WT
CD8C T cells. Furthermore, the absence of Akt3 has no effect on
the percentage of TCM cells and is comparable to cells from WT
mice.
This suggests that, in CD8C T cells, Akt1 and -2 push toward
the more powerful and acute TEM response. Although this is the
desired situation in cases of acute infections, a continuous expo-
sure to the antigen in cases of chronic infections and tumors leads
to depletion of the TEM cells and the small reservoir of TCM
CD8C T cells. The inhibition of Akt1 and Akt2 isoforms seems
to reverse this effect and favors a more sustainable response with-
out affecting the number or function of available CD8C T cells.
Here, we report that Akt1 and Akt2, but not Akt3, drive the
terminal differentiation of CD8C T cells and that their inhibition
enhances the TCM phenotype, improves CD8
C T-cell survival,
prolongs their cytokine and Granzyme B production ability, and
enhances their proliferative potential.
To date, mechanisms that slow down terminal differentiation
of CD8C T cells without substantially impacting proliferation
after T-cell receptor (TCR) stimulation are still lacking. Here, we
define a mechanism in which proliferative potential, function, and
survival are enhanced by maintaining a reservoir of TCM and
na€ıve cells using only Akt1 and -2 inhibition. These findings
strongly suggest the utility of using Akt isoform inhibitors to
modulate the immune response as part of cancer immune therapy.
Materials and Methods
Mice and reagents
In vitro experiments used pMel-1 mice [B6.Cg-Thy1a/Cy Tg
(TcraTcrb)8Rest/J] that carry a rearranged TCR transgene
(Vb13) specific for the mouse homolog (pmel-17) of human
(gp100).26 C57BL/6(H-2b) WT, Akt1 KO, Akt2 KO, and Akt3
KO mice were also used. Akt3 KO mice were a generous gift
from Dr Morris Birnbaum (University of Pennsylvania, PA) and
Dr Phillip Dennis (NCI, NIH, MD) and were extensively back-
crossed onto WT C57BL/6(H-2b) mice. All other mouse strains
were purchased from the Jackson Laboratory. The animals were
housed under pathogen-free conditions.
MK-2206 was purchased from Selleckchem. It is a highly selec-
tive inhibitor of all Akt isoforms with an IC50 of 8 nmol/L for
Akt1, 12 nmol/L for Akt2, and 65 nmol/L for Akt3. The inhibitor
was used in vitro at an optimized concentration of 0.67 mmol/L.
AZD5363 was purchased from Selleckchem. It is a highly specific
Akt inhibitor and has an IC50 of 3 nmol/L for Akt1, 8 nmol/L for
Akt2, and 8 nmol/L for Akt3. The inhibitor was used in vitro at the
optimized concentration of 2.4 mmol/L. The Akt kinase 1/2 inhibi-
tor [1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxa-
lin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one tri-
fluoroacetate salt hydrate (Sigma)] has an IC50 of 58 nmol/L for
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Akt1 and 210 nmol/L for Akt2 and only inhibits Akt3 at a concen-
tration of 2.12 mmol/L. The inhibitor was used in vitro at the opti-
mal concentration of 2.2 mmol/L, which is 103-fold lower than the
IC50 for Akt3 and, therefore, ensures specificity for Akt1 and Akt2.
The inhibitors were titrated based on the IC50 of specific isoforms,
and the doses used showed optimal inhibition with minimal effect
on viability. Pan Akt inhibitors were used at doses ensuring the
inhibition of all 3 isoforms.
The gp10025–33 9-mer peptide (KVPRNQDWL) (ANAS-
PEC) was used for in vitro activation of pMel-1 splenocytes at a
1 mmol/L concentration. Briefly, GP100 is an enzyme involved
in pigment synthesis that is expressed by different melanoma cell
lines (including B16) and normal melanocytes.
CD8C enrichment kits (Miltenyi) were used according to the
manufacturer’s instructions. Fluorochrome-labeled antibodies
used for flow cytometry were purchased from BD.
In Vitro activation of CD8C T cells
Tumor antigen-specific CD8C T cells
Unfractionated splenocytes from pMel-1 mice were homoge-
nized and stimulated in vitro by gp10025–33 peptide at a 1 mmol/
L concentration (Day 0). Cells were cultured in RPMI-1640
(Lonza) supplemented with 10% fetal bovine serum (FBS), peni-
cillin (100 U/mL), streptomycin (100 mg/mL), 0.1% b-mercap-
toethanol (Life Technologies, Invitrogen), and IL-2 (100 U/mL)
(Peprotech) at 37C with 5% CO2. The cells were cultured with
or without MK-2206 (0.67, 2, or 6 mmol/L), AZD5363 (0.27,
0.81, or 2.4 mmol/L), or Akt-1/2 inhibitor (2.2, 6.7, or 20.1
mmol/L). The concentration of the inhibitors was maintained
throughout the culture by changing the media every 48–72 h.
On days 7, 14, and 21, cells were re-stimulated with gp10025–
33 peptide at a 1 mmol/L concentration using feeder cells (irradi-
ated WT splenocytes, 4,000 Rads) at 1:1 ratio using the same
culture conditions.
TCR stimulation and co-stimulation
The CD8C T cells from WT, Akt1 KO, Akt2 KO, and Akt3
KO mice were enriched using CD8C enrichment kits (Miltenyi)
according to the manufacturer’s instructions (purity was on aver-
age 91%) or CD8C cells were sorted using FACS ARIA II (BD
Biosciences; purity > 99%).
The cells were then stimulated using feeder cells (irradiated
WT splenocytes, 4000 Rads) at 1:1 ratio (Day 0) using TCR
stimulation (anti-CD3 antibody 1 mg/mL, BD Biosciences) and
co-stimulation (anti-CD28 antibody 2.5 mg/mL BD Biosciences)
in the presence of 100 U/mL IL-2 (Peprotech). The cells were
cultured with or without the optimized doses of the inhibitors
MK-2206 at a 0.67 mmol/L concentration or Akt-1/2 inhibitor at
a concentration of 2.2 mmol/L, and the concentration was main-
tained throughout the culture by changing the media every 48–
72 h. Cells were cultured in the same conditions described earlier.
Proliferation assay and phenotyping of CD8C T cells
Prior to their stimulation (Day 0), cells were labeled with 5
mmol/L VCT proliferation dye (Life Technologies, Invitrogen)
according to the manufacturers’ instructions. Samples were then
evaluated for CD8C T-cell expansion via VCT dye dilution (Day
3) using an LSRII SORP with HTS Flow Cytometer (BD Bioscien-
ces). The data were analyzed using FlowJo 9 or 10 (Tree Star).
To assess the phenotype of the T cells, the cultured cells were har-
vested and analyzed on days 3, 7, 14, and 21. The cells were stained
with APC-Cy7-labeled anti-CD8, fluorescein isothiocyanate
(FITC)-labeled anti-Vb13, phycoerythrin (PE) labeled anti-CD62L,
APC-labeled anti-CD44, PE-CF594-labeled anti-CD127, and
APC-labeled anti-KLRG-1 in addition to the viability stain 7AAD
(BD Biosciences). The same APC-Cy7-labeled anti-CD8 was used
for sorting the cells using the FACS ARIA II (BD Biosciences).
For proliferation and phenotyping, the analyses were con-
ducted on CD8C T cells specific for the gp100 antigen and were
gated on viable (7AAD-), Vb13CCD8C T cells. For WT and
KO cells, the cells were gated on viable (7AAD-), CD8C T cells.
For intracellular staining, cells were stained with the fixable
near infrared Live/Dead viability stain (Life Technologies, Invi-
trogen), and fixed, permeabilized, and stained with APC-labeled
anti-CD8, V450-labeled anti-Vb13, PE-labeled anti-CD62L,
and PE-CF594-labeled anti-CD44 (BD Biosciences), and FITC-
labeled Granzyme B (Biolegend). The analyses were conducted
on CD8C T cells specific for the gp100 antigen and were gated
on viable (Live/Dead negative), Vb13CCD8C T cells.
Cytometric bead array
Following the same activation protocol mentioned earlier, the
pMel-1 gp100-specific CD8C T cells were harvested on Day 7
after the first and second stimulation. The viable cells (trypan
blue negative) were then counted and co-incubated (at 1:1 ratio)
with 1 mmol/L gp10025–33 pulsated irradiated splenocytes (4000
Rads) for 24 h using the same culture conditions. The superna-
tant was collected and the levels of IL-2, TNF, and IFNg were
assessed using the mouse Th1/Th2/Th17 Cytokine Kit BDTM
Cytometric Bead Array (CBA) kit. The data were collected using
an LSRII SORP with HTS flow cytometer (BD Biosciences), and
analyzed using the FCAP Array Software v3.0 (BD Biosciences).
Statistical analysis
All statistical parameters (average values, SD, significant dif-
ferences between groups) were calculated using GraphPad Prism
Software. Statistical significance between groups was determined
by paired t-test or one-way ANOVA with post hoc Tukey’s multi-
ple comparison test (P < 0.05 was considered statistically
significant).
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
The authors thank Dr Esteban Celis and Dr Rhea-Beth
Markowitz for reviewing the manuscript and for their valuable
suggestions and also thank Dr Lei Huang for his suggestions.
e1005448-10 Volume 4 Issue 5OncoImmunology
Funding
This work was supported by the Georgia Regents University
Cancer Center (GRUCC) and a Fellowship Grant from King
Hussein Institute for Biotechnology and Cancer (KHIBC, Jordan
to RAE).
Supplemental Material
Supplemental data for this article can be accessed on the
publisher’s website.
References
1. Kim EH, Suresh M. Role of PI3K/Akt signaling in
memory CD8 T cell differentiation. Front Immunol
2013; 4:20; PMID:23378844
2. Klebanoff CA, Gattinoni L, Restifo NP. CD8C T-cell
memory in tumor immunology and immunotherapy.
Immunol Rev 2006; 211:214–24; PMID:16824130;
http://dx.doi.org/10.1111/j.0105-2896.2006.00391.x
3. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia
A. Two subsets of memory T lymphocytes with distinct
homing potentials and effector functions. Nature 1999;
401:708–12; PMID:10537110; http://dx.doi.org/
10.1038/44385
4. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann
K, Cardones AR, Finkelstein SE, Palmer DC, Antony
PA, Hwang ST, Rosenberg SA, et al. Central memory
self/tumor-reactive CD8C T cells confer superior anti-
tumor immunity compared with effector memory T




SM, Antia R, , von Andrian UH, Ahmed R. Lineage rela-
tionship and protective immunity of memory CD8 T cell
subsets. Nat Immunol 2003; 4:225–34;
PMID:12563257;http://dx.doi.org/10.1038/ni889
6. Rosenberg SA, Sherry RM, Morton KE, Scharfman
WJ, Yang JC, Topalian SL, Royal RE, Kammula U,
Restifo NP, Hughes MS, et al. Tumor progression can
occur despite the induction of very high levels of self/
tumor antigen-specific CD8C T cells in patients with
melanoma. J Immunol 2005; 175:6169–76;
PMID:16237114; http://dx.doi.org/10.4049/
jimmunol.175.9.6169
7. Roberts AD, Ely KH, Woodland DL. Differential con-
tributions of central and effector memory T cells to
recall responses. J Exp Med 2005; 202:123–33;
PMID:15983064; http://dx.doi.org/10.1084/
jem.20050137
8. Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, et al.
Human effector T cells derived from central memory
cells rather than CD8T cells modified by tumor-specific
TCR gene transfer possess superior traits for adoptive
immunotherapy. Cancer Lett 2013; 339(2):195–207.
9. Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A,
Choi KY, Suresh M. Signal integration by Akt regulates
CD8 T cell effector and memory differentiation. J
Immunol 2012; 188:4305–14; PMID:22467649;
http://dx.doi.org/10.4049/jimmunol.1103568
10. Finlay D, Cantrell D. Phosphoinositide 3-kinase and
the mammalian target of rapamycin pathways control
T cell migration. Ann N Y Acad Sci 2010; 1183:149–
57; PMID:20146713; http://dx.doi.org/10.1111/
j.1749-6632.2009.05134.x
11. Kane LP, Weiss A. The PI-3 kinase/Akt pathway and T
cell activation: pleiotropic pathways downstream of
PtdIns(3,4,5)P3. Immunol Rev 2003; 192:7–20;
PMID:12670391; http://dx.doi.org/10.1034/j.1600-
065X.2003.00008.x
12. Mao C, Tili EG, Dose M, Haks MC, Bear SE, Marou-
lakou I, Horie K, Gaitanaris GA, Fidanza V, Ludwig
T, et al. Unequal contribution of Akt isoforms in the
double-negative to double-positive thymocyte transi-
tion. J Immunol 2007; 178:5443–53;
PMID:17442925; http://dx.doi.org/10.4049/
jimmunol.178.9.5443
13. Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC,
Koretzky GA. Akt1 and Akt2 are required for alphabeta
thymocyte survival and differentiation. Proc Natl Acad
Sci U S A 2007; 104:12105–10; PMID:17609365;
http://dx.doi.org/10.1073/pnas.0705285104
14. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K,
Gillanders W, Shrikant PA. Regulating mammalian
target of rapamycin to tune vaccination-induced CD8
(C) T cell responses for tumor immunity. J Immunol
2012; 188:3080–7; PMID:22379028; http://dx.doi.
org/10.4049/jimmunol.1103365
15. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller
SA, Bachmann MF, Larsen CP, Ahmed R. mTOR reg-
ulates memory CD8 T-cell differentiation. Nature
2009; 460:108–12; PMID:19543266; http://dx.doi.
org/10.1038/nature08155
16. Mineharu Y, Kamran N, Lowenstein PR, Castro MG.
Blockade of mTOR signaling via rapamycin combined
with immunotherapy augments anti-glioma cytotoxic
and memory t cells’ functions. Mol Cancer Ther 2014;
13(12):3024–36; PMID:25256739
17. Kim HL. Antibody-based depletion of Foxp3C T cells
potentiates antitumor immune memory stimulated by
mTOR inhibition. Oncoimmunology 2014; 3:e29081;
PMID:25083329; http://dx.doi.org/10.4161/
onci.29081
18. Long SA, Buckner JH. Combination of rapamycin and
IL-2 increases de novo induction of human CD4(C)
CD25(C)FOXP3(C) T cells. J Autoimmun 2008;
30:293–302; PMID:18313267; http://dx.doi.org/
10.1016/j.jaut.2007.12.012
19. Strauss L, Whiteside TL, Knights A, Bergmann C,
Knuth A, Zippelius A. Selective survival of naturally
occurring human CD4CCD25CFoxp3C regulatory T
cells cultured with rapamycin. J Immunol 2007;
178:320–9; PMID:17182569; http://dx.doi.org/
10.4049/jimmunol.178.1.320
20. Battaglia M, Stabilini A, Roncarolo MG. Rapamy-
cin selectively expands CD4CCD25CFoxP3C regu-
latory T cells. Blood 2005; 105:4743–8;
PMID:15746082; http://dx.doi.org/10.1182/blood-
2004-10-3932
21. Basu S, Golovina T, Mikheeva T, June CH, Riley JL.
Cutting edge: Foxp3-mediated induction of pim 2
allows human T regulatory cells to preferentially
expand in rapamycin. J Immunol 2008; 180:5794–8;
PMID:18424697; http://dx.doi.org/10.4049/
jimmunol.180.9.5794
22. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu
H, Khuri FR. Activation of Akt and eIF4E survival
pathways by rapamycin-mediated mammalian target of
rapamycin inhibition. Cancer Res 2005; 65:7052–8;
PMID:16103051; http://dx.doi.org/10.1158/0008-
5472.CAN-05-0917
23. Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Ber-
zofsky JA, Friedman KM, Mkrtichyan M, Khleif SN.
Selective inhibition of regulatory T cells by targeting
the PI3K-Akt pathway. Cancer Immunol Res 2014;
2:1080–9; PMID:25080445; http://dx.doi.org/
10.1158/2326-6066.CIR-14-0095
24. Wen M, Xu W, Ren L, Gao F, Cui N, Wen J, Li X, Lin
L, Ma Z, Chen B, et al. Effector cells derived from
naive T cells used in tumor immunotherapy of mice
bearing B16 melanoma. Chin Med J (Engl) 2014;
127:1328–33; PMID:24709189
25. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns
WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP,
Yang S, et al. Human effector CD8C T cells derived
from naive rather than memory subsets possess superior
traits for adoptive immunotherapy. Blood 2011;
117:808–14; PMID:20971955; http://dx.doi.org/
10.1182/blood-2010-05-286286
26. B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J. The Jackson
Laboratory; 2004. Available at: http://jaxmice.jax.org/
strain/005023.html
www.tandfonline.com e1005448-11OncoImmunology
